This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinates of Health
Disparities: Social Determinates of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinates of Health
Clinical Trials
From the Editor
Search Clinical Trials
Trials in Progress
DORA - PCCTC
IRONMAN - PCCTC
PROMISE - PCCTC
SPLASH Trial
Oral EPI-7386
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO GU 2023
EAU 2023
SES AUA 2023
All Conferences
View All
PCF
UroToday Home
Video Lectures
ASCO 2021
ASCO 2021 VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
The Optimal Timing for Starting Avelumab Maintenance After Completing First-line Chemotherapy, JAVELIN Bladder 100 - Srikala Sridhar
Details
The phase 3 JAVELIN Bladder 100 trial demonstrated that First-line maintenance therapy with avelumab + best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone, while the optimal timing for starting avelumab after completing first-line (1L) chemotherapy is still unknown. In a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meetin...
Patient Preference Study Evaluating Darolutamide and Enzalutamide in Men with mCRPC - Karim Fizazi
Details
In this conversation with Alicia Morgans, MD, MPH, Karim Fizazi shares trial results from the phase II ODENZA trial presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ODENZA is a French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metasta...
Real-World Data Demonstrates Limited Treatment Intensification for Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and Disparities by Race - Stephen Freedland
Details
Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a retrospective analysis of the Medicare database from January 2009-Dec 2018 on the real-world use of advanced therapies over time and the use of patterns among racial minorities that are often under-represented in clinical trials. These data were presented at the ASCO 2021 Annual Meeting. The researchers examined 35,195 patients in...
Apalutamide Improves Overall Survival and rPFS While Preserving Health-Related Quality of Life in Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Neeraj Agarwal
Details
The TITAN Study is the pivotal phase III trial demonstrating the benefit of apalutamide in mHSPC. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Neeraj Agarwal, MD, presented the health-related quality of life (HRQoL) data from this final analysis after cross-over from the phase III TITAN trial. In this conversation with Alicia Morgans, MD, MPH, he highlights this data. T...
Start
Prev
1
2
3
4
5
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free